Interventional, Randomized, Double-blind, Sequential Cohort, Placebo-controlled, Multiple-dose Trial Investigating the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of Lu AG06474 in Healthy Young Men and Women, With an Open-label, Cross-over, Single-dose Part Investigating the Relative Bioavailability of a Capsule Formulation
Latest Information Update: 22 Nov 2024
At a glance
- Drugs Lu AG06474 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lundbeck A/S
Most Recent Events
- 18 Nov 2024 Status changed from recruiting to discontinued.
- 02 Aug 2023 Planned End Date changed from 22 Sep 2024 to 15 Aug 2024.
- 02 Aug 2023 Planned primary completion date changed from 22 Sep 2024 to 11 Aug 2024.